Table 3.
Drugs that directly target HCV (STAT-C) and phase of clinical trials (phases 2 and 3)
| Drug | Company | Phase |
|---|---|---|
| Entry inhibitor | ||
| ITX5061 | iTherX (formerly Immusol) | 2 |
| Protease inhibitor | ||
| Telaprevir | Vertex | 3 |
| Boceprevir (SCH503034) | Schering | 3 |
| ITMN-191/R7227 | Intermune/Roche | 2 |
| TMC435 | Medivir/Tibotec | 2 |
| BI 201335 | Boehringer Ingelheim | 2 |
| MK-7009 | Merck | 2 |
| NS5A inhibitor | ||
| BMS-790052 | Bristol-Myers Squibb | 2 |
| Polymerase inhibitor/Nucleoside polymerase inhibitor | ||
| R7128 | Roche/Pharmasset | 2 |
| Polymerase inhibitor/Non-nucleoside polymerase inhibitor | ||
| PF-868554 | Pfizer | 2 |
| ANA598 | Anadys | 2 |
| VCH-759 | ViroChem Pharma (acquired by Vertex) | 2 |
| IDX184 | Idenix | 2 |
| Therapeutic Vaccines | ||
| IC41 | Intercell Novartis | 2 |
| CSL123 | Chiron/CSL | 2 |
| GI 5005 | Globeimmune | 2 |
Hepatitis C new drug pipeline (http://www.hcvdrugs.com, accessed on 2/9/2010)